Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study
Isobel Ward, Charlotte Bermingham, Daniel Ayoubkhani, et al.
BMJ (2022), pp. e070695-e070695
Open Access | Times Cited: 156

Showing 1-25 of 156 citing articles:

Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods — United States, April 2020–June 2022
Stacey Adjei, Kai Hong, Noelle‐Angelique Molinari, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 37, pp. 1182-1189
Open Access | Times Cited: 153
Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study
José Villar, Constanza P. Soto Conti, Robert B. Gunier, et al.
The Lancet (2023) Vol. 401, Iss. 10375, pp. 447-457
Open Access | Times Cited: 122
Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
Rachael A. Evans, Sabada Dube, Yi Lu, et al.
The Lancet Regional Health - Europe (2023) Vol. 35, pp. 100747-100747
Open Access | Times Cited: 95
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1760-1774
Open Access | Times Cited: 80
Current and Emerging Knowledge in COVID-19
Yeon Joo Jeong, Yu Mi Wi, Hyunjin Park, et al.
Radiology (2023) Vol. 306, Iss. 2
Open Access | Times Cited: 72
Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform
Linda Nab, Edward P K Parker, Colm Andrews, et al.
The Lancet Public Health (2023) Vol. 8, Iss. 5, pp. e364-e377
Open Access | Times Cited: 59
Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019–positive patients
Feihong Hu, Yijie Jia, Dan‐Yan Zhao, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 7, pp. 835-844
Open Access | Times Cited: 56
Severity of the Omicron SARS‐CoV‐2 variant compared with the previous lineages: A systematic review
Maryam Arabi, Yousef Al‐Najjar, Nada Mhaimeed, et al.
Journal of Cellular and Molecular Medicine (2023) Vol. 27, Iss. 11, pp. 1443-1464
Open Access | Times Cited: 51
Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis
Pryanka Relan, Nkengafac Villyen Motaze, Kavita Kothari, et al.
BMJ Global Health (2023) Vol. 8, Iss. 7, pp. e012328-e012328
Open Access | Times Cited: 49
In-hospital mortality during the wild-type, alpha, delta, and omicron SARS-CoV-2 waves: a multinational cohort study in the EuCARE project
Pontus Hedberg, Miłosz Parczewski, Karol Serwin, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100855-100855
Open Access | Times Cited: 18
Evolution and Control of COVID-19 Epidemic in Hong Kong
Shuk‐Ching Wong, Albert Ka-Wing Au, Janice Lo, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2519-2519
Open Access | Times Cited: 47
The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5
Huiping Shuai, Jasper Fuk‐Woo Chan, Bingjie Hu, et al.
EBioMedicine (2023) Vol. 95, pp. 104753-104753
Open Access | Times Cited: 35
Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 – February 2022)
Daniele Petrone, Alberto Mateo‐Urdiales, Chiara Sacco, et al.
International Journal of Infectious Diseases (2023) Vol. 129, pp. 135-141
Open Access | Times Cited: 34
Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review
Pradipta Paul, Ahmed El-Naas, Omar Hamad, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 34
Evaluation of the US COVID-19 Scenario Modeling Hub for informing pandemic response under uncertainty
Emily Howerton, Lucie Contamin, Luke C. Mullany, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 32
Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients
Cheng‐Zhao Weng, Rongcheng Xie, Guanjie Han, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 2, pp. 649-662
Open Access | Times Cited: 28
Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study
Julia Hippisley‐Cox, Kamlesh Khunti, Aziz Sheikh, et al.
BMJ (2023), pp. e072976-e072976
Open Access | Times Cited: 27
The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review
Aparajita Sarkar, Sara Omar, Aya Alshareef, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 24
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 23
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Jaap A. van Doesum, Jon Salmanton‐García, Francesco Marchesi, et al.
Blood Advances (2023) Vol. 7, Iss. 11, pp. 2645-2655
Open Access | Times Cited: 21
Comparative analysis of mortality in patients admitted with an infection with influenza A/B virus, respiratory syncytial virus, rhinovirus, metapneumovirus or SARS‐CoV‐2
Hanneke Boon, Arend‐Jan Meinders, Erik J. van Hannen, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 12
SARS-CoV-2 Viral Replication Persists in the Human Lung for Several Weeks after Symptom Onset
Michele Tomasicchio, Shameem Z. Jaumdally, Lindsay Wilson, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 209, Iss. 7, pp. 840-851
Open Access | Times Cited: 9
Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review
Maryam Arabi, Yousef Al‐Najjar, Omna Sharma, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 20
Clinical outcomes and phylogenetic analysis in reflection with three predominant clades of SARS‐CoV‐2 variants
Kameran M. Ali, Peshnyar M.A. Rashid, Ayad M. Ali, et al.
European Journal of Clinical Investigation (2023) Vol. 53, Iss. 9
Open Access | Times Cited: 19
Comparison of Clinical Characteristics and Mortality Outcome in Critical COVID-19 Patients Infected with Alpha and Omicron Variants
Hsin-I Cheng, Ko‐Wei Chang, Bing-Chen Wu, et al.
Infection and Drug Resistance (2025) Vol. Volume 18, pp. 151-160
Open Access
Page 1 - Next Page

Scroll to top